Evidence map›Paper›PMID 39150050›Full record

ArticleJournal of hepato-biliary-pancreatic sciences2024

Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1).

Naohiro Okano, Manabu Kawai, Makoto Ueno, Xianjun Yu, Yosuke Inoue, Shinichiro Takahashi, Wenquan Wang, Hidenori Takahashi, Yukiyasu Okamura, Soichiro Morinaga and 13 more

Erratum issuedAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepato-biliary-pancreatic sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Analysis of Hepatic Artery Reconstruction in Advanced Pancreatic Head Cancer.Plastic and reconstructive surgery. Global open · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Naohiro OkanoDepartment of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4098-5217
Manabu KawaiSecond Department of Surgery, Wakayama Medical University School of Medicine, Wakayama, Japan.ORCID https://orcid.org/0000-0003-3506-9895
Makoto UenoDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Xianjun YuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Yosuke InoueDivision of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID https://orcid.org/0000-0001-5812-6608
Shinichiro TakahashiDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0002-4828-3965
Wenquan WangDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Hidenori TakahashiDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Yukiyasu OkamuraDivision of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Soichiro MorinagaDepartment of Hepato-Biliary and Pancreatic Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Ippei MatsumotoDepartment of Surgery, Kindai University Faculty of Medicine, Osakasayama, Japan.ORCID https://orcid.org/0000-0003-3965-3693
Yasuhiro ShimizuDepartment of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID https://orcid.org/0000-0002-2003-6110
Kazuhiro YoshidaDepartment of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan.
Tomohisa YamamotoDepartment of Surgery, Kansai Medical University, Hirakata, Japan.
Masayuki OhtsukaDepartment of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yoshikuni InokawaDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0002-1412-1124
Satoshi NaraDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0002-3516-8765
Jun TamuraDepartment of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.
Satoru ShinodaDepartment of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.
Kouji YamamotoDepartment of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.
Hiroki YamaueSecond Department of Surgery, Wakayama Medical University School of Medicine, Wakayama, Japan.ORCID https://orcid.org/0000-0002-6982-3457
Junji FuruseDepartment of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.
PC‐CURE‐1 study group

Funding

Federation of Asian Clinical Oncology
6 · The paper itself

Abstract

backgroundThe efficacy and safety of conversion surgery (CS) after FOLFIRINOX or gemcitabine plus nab-paclitaxel (GnP) chemotherapy in patients with initially unresectable pancreatic cancer (PC) remains unclear.

methodsThis multicenter retrospective cohort study enrolled patients, between 2014 and 2018, with initially locally advanced or metastatic PC who were considered candidates for CS following FOLFIRINOX or GnP chemotherapy. They were classified into surgery (207 patients [194 resection and 13 exploratory laparotomy only]) and continued chemotherapy (10 patients, control) groups. The primary endpoint was overall survival (OS) from the day of diagnosis of potentially curative resection on imaging studies, with an expected hazard ratio (HR) of 0.7.

resultsOS in the surgery group was longer than that in the control group (HR, 0.47; 95% confidence interval [CI]: 0.24-0.93). The median OS was 34.4 (95% CI: 27.9-43.4) and 19.8 (95% CI: 14.9-31.1) months in the surgery and control groups, respectively. The Clavien-Dindo grade ≥ IIIa postoperative complication and in-hospital mortality rates were 19.6% and 0.5%, respectively. Multivariate analysis revealed that preoperative chemotherapy duration was not associated with OS.

conclusionsCS, following a favorable response to FOLFIRINOX or GnP chemotherapy, improved initially unresectable PC prognosis (specifically, OS), regardless of the chemotherapy duration.

Indexed as

AlbuminsAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineFluorouracilGemcitabineIrinotecanLeucovorinOxaliplatinPaclitaxelPancreatic NeoplasmsAdultAgedCohort StudiesFemaleHumansMale130-nm albumin-bound paclitaxelAlbuminsDeoxycytidineFluorouracilfolfirinoxGemcitabineIrinotecanLeucovorinOxaliplatinPaclitaxelalbumin‐bound paclitaxelFOLFIRINOXgemcitabinepancreatic cancersurgery

Identifiers

PMID39150050
PMCPMC11589395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.